---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123437"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:39:27.267653+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs Q3 net loss $23.4M; IPO proceeds extend cash runway into 2029

## Summary
- Net loss of $23.4M ($6.70/share) vs $14.6M ($8.74/share) in Q3 2023; R&D spend rose to $20.0M on Phase 2 STRIDES trial.
- Cash and cash equivalents at Sept. 30, 2024: $334.5M, with additional $27.6M from underwriter option in Oct. 2024.
- IPO and concurrent private placement yielded ~$189.5M net, plus $27.6M from underwriter option; cash sufficient into 2029.
- Phase 2 STRIDES trial of azelaprag + tirzepatide for obesity dosed first patient; top-line results expected Q3 2025.
- Appointed former GSK CEO Jean-Pierre Garnier as Board Chair, succeeding James Healy who remains a director.

## SEC filing metadata
- accession: 0000950170-24-123437
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000095017024123437/0000950170-24-123437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000095017024123437/bioa-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123437
- JSON: https://secwatch.observer/filing/0000950170-24-123437.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.